Effect of Disrupted SOX18 Transcription Factor Function on Tumor Growth, Vascularization, and Endothelial Development

Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med1971 ; 285 : 1182 –6.

Fernando NH, Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol2003 ; 30 : 39 –50.

Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med2003 ; 349 : 427 –34.

Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature2000 ; 407 : 249 –57.

Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med2000 ; 6 : 389 –95.

Bowles J, Schepers G, Koopman P. Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators. Dev Biol2000 ; 227 : 239 –55.

Hosking BM, Wyeth JR, Pennisi DJ, Wang SC, Koopman P, Muscat GE. Cloning and functional analysis of the Sry-related HMG box gene, Sox18. Gene2001 ; 262 : 239 –47.

Pennisi DJ, James KM, Hosking B, Muscat GE, Koopman P. Structure, mapping, and expression of human SOX18. Mamm Genome2000 ; 11 : 1147 –9.

Hosking BM, Wang SC, Chen SL, Penning S, Koopman P, Muscat GE. SOX18 directly interacts with MEF2C in endothelial cells. Biochem Biophys Res Commun2001 ; 287 : 493 –500.

Hosking BM, Wang SC, Downes M, Koopman P, Muscat GE. The VCAM-1 gene that encodes the vascular cell adhesion molecule is a target of the Sry-related high mobility group box gene, Sox18. J Biol Chem2004 ; 279 : 5314 –22.

Hosking BM, Muscat GE, Koopman PA, Dowhan DH, Dunn TL. Trans-activation and DNA-binding properties of the transcription factor, Sox-18. Nucleic Acids Res1995 ; 23 : 2626 –8.

Irrthum A, Devriendt K, Chitayat D, Matthijs G, Glade C, Steijlen PM, et al. Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia. Am J Hum Genet2003 ; 72 : 1470 –8.

Green E, Mann SJ. Opossum, a semi-dominant lethal mutation affecting hair and other characteristics of mice. J Hered1961 ; 52 : 223 –7.

Greenfield A, Dunn T, Muscat G, Koopman P. The Sry-related gene Sox18 maps to distal mouse chromosome 2. Genomics1996 ; 36 : 558 –9.

Pennisi D, Gardner J, Chambers D, Hosking B, Peters J, Muscat G, et al. Mutations in Sox18 underlie cardiovascular and hair follicle defects in ragged mice. Nat Genet2000 ; 24 : 434 –7.

James K, Hosking B, Gardner J, Muscat GE, Koopman P. Sox18 mutations in the ragged mouse alleles ragged-like and opossum. Genesis2003 ; 36 : 1 –6.

Pennisi D, Bowles J, Nagy A, Muscat G, Koopman P. Mice null for sox18 are viable and display a mild coat defect. Mol Cell Biol2000 ; 20 : 9331 –6.

Fawcett SR, Klymkowsky MW. Embryonic expression of Xenopus laevis SOX7. Gene Expr Patterns2004 ; 4 : 29 –33.

Downes M, Koopman P. SOX18 and the transcriptional regulation of blood vessel development. Trends Cardiovasc Med2001 ; 11 : 318 –24.

Kanai-Azuma M, Kanai Y, Gad JM, Tajima Y, Taya C, Kurohmaru M, et al. Depletion of definitive gut endoderm in Sox17-null mutant mice. Development2002 ; 129 : 2367 –79.

Saitoh T, Katoh M. Expression of human SOX18 in normal tissues and tumors. Int J Mol Med2002 ; 10 : 339 –44.

Katoh M. Expression of human SOX7 in normal tissues and tumors. Int J Mol Med2002 ; 9 : 363 –8.

Katoh M. Molecular cloning and characterization of human SOX17. Int J Mol Med2002 ; 9 : 153 –7.

Teicher BAA, P.A. Anticancer Drug Development Guide, 2nd edition. Totowa (NJ): Humana Press; 1997 .

Hahn CN, Su ZJ, Drogemuller CJ, Tsykin A, Waterman SR, Brautigan PJ, et al. Expression profiling reveals functionally important genes and coordinately regulated signaling pathway genes during in vitro angiogenesis. Physiol Genomics2005 ; 22 : 57 –69.

Jackson DE. The unfolding tale of PECAM-1. FEBS Lett2003 ; 540 : 7 –14.

Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res2003 ; 314 : 15 –23.

Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays1991 ; 13 : 31 –6.

Themistocleous GS, Katopodis H, Sourla A, Lembessis P, Doillon CJ, Soucacos PN, et al. Three-dimensional type I collagen cell culture systems for the study of bone pathophysiology. In Vivo2004 ; 18 : 687 –96.

Meyer GT, Matthias LJ, Noack L, Vadas MA, Gamble JR. Lumen formation during angiogenesis in vitro involves phagocytic activity, formation and secretion of vacuoles, cell death, and capillary tube remodelling by different populations of endothelial cells. Anat Rec1997 ; 249 : 327 –40.

Gamble JR, Matthias LJ, Meyer G, Kaur P, Russ G, Faull R, et al. Regulation of in vitro capillary tube formation by anti-integrin antibodies. J Cell Biol1993 ; 121 : 931 –43.

Ding L, Donate F, Parry GC, Guan X, Maher P, Levin EG. Inhibition of cell migration and angiogenesis by the amino-terminal fragment of 24kD basic fibroblast growth factor. J Biol Chem2002 ; 277 : 31056 –61.

Meadows KN, Bryant P, Pumiglia K. Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J Biol Chem2001 ; 276 : 49289 –98.

Banks GC, Deterding LJ, Tomer KB, Archer TK. Hormone-mediated dephosphorylation of specific histone H1 isoforms. J Biol Chem2001 ; 276 : 36467 –73.

Talasz H, Helliger W, Puschendorf B, Lindner H. In vivo phosphorylation of histone H1 variants during the cell cycle. Biochemistry1996 ; 35 : 1761 –7.

Meadows KN, Bryant P, Vincent PA, Pumiglia KM. Activated Ras induces a proangiogenic phenotype in primary endothelial cells. Oncogene2004 ; 23 : 192 –200.

Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrup P, Everitt L, et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A1999 ; 96 : 2811 –6.

Troyanovsky B, Levchenko T, Mansson G, Matvijenko O, Holmgren L. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol2001 ; 152 : 1247 –54.

Review. Bevacizumab. Anti-VEGF monoclonal antibody, avastin, rhumab-VEGF. Drugs R D2002 ; 3 : 28 –30.

Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst2002 ; 94 : 883 –93.

Zhang W, Ran S, Sambade M, Huang X, Thorpe PE. A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis2002 ; 5 : 35 –44.

Deroanne CF, Lapiere CM, Nusgens BV. In vitro tubulogenesis of endothelial cells by relaxation of the coupling extracellular matrix-cytoskeleton. Cardiovasc Res2001 ; 49 : 647 –58.

Garcia-Ramirez M, Martinez-Gonzalez J, Juan-Babot JO, Rodriguez C, Badimon L. Transcription factor SOX18 is expressed in human coronary atherosclerotic lesions and regulates DNA synthesis and vascular cell growth. Arterioscler Thromb Vasc Biol2005 ; 25 : 2398 –403.

Salameh A, Galvagni F, Bardelli M, Bussolino F, Oliviero S. Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. Blood2005 ; 106 : 3423 –31.

Redell MS, Tweardy DJ. Targeting transcription factors for cancer therapy. Curr Pharm Des2005 ; 11 : 2873 –87.

Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science2002 ; 296 : 2404 –7.